News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gentium S.p.A. Shareholders Sue Over $1 Billion Jazz Pharmaceuticals plc (JAZZ) Deal


1/17/2014 7:21:23 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Shareholders of Gentium SpA filed a case against the company's board in a bid to halt Jazz Pharmaceuticals Plc from acquiring it, Bloomberg reported. The shareholders claimed that the deal, valued at $1 billion is "hopelessly flawed." A biopharmaceutical firm, Gentium concentrates on discovering, researching and manufacturing therapies to treat and prevent a number of vascular diseases and cancer-related conditions. Jazz Pharmaceuticals, meanwhile, identifies, develops and commercializes products for narcolepsy, oncology, pain and psychiatry.

Help employers find you! Check out all the jobs and post your resume.

Read at News Release
Read at Bloomberg
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES